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Abstract
Multiple myeloma (MM) is a plasma cell disorder, characterised by bone marrow infiltration with clonal plasma 
cells; production of monoclonal immunoglobulin (paraprotein); end-organ damage; lytic lesions in the bones; renal 
impairment; hypercalcaemia and anaemia. Skeleton evaluation in MM is necessary not only for staging purposes but 
also to detect serious complications such as fractures. Skeletal survey is an established first-line investigation for this 
purpose. However, in recent years, new imaging techniques such as whole-body magnetic resonance imaging and 
2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography have been used widely. In this 
article, we review different imaging techniques used in MM and their impact on patient management.
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Introduction
Multiple myeloma (MM) is a plasma cell malignancy. 
The aetiology of MM is unknown and it accounts for 
10% of haematological malignancies and nearly 1% of 
all cancers.[1] Median age at presentation is 70 years and 
only 2–3% of patients are younger than 40 years. MM has 
slight male predominance and is more common among 
African Americans than white Americans or Europeans.[2] 
MM is characterised by bone marrow (BM) infiltration 
with clonal plasma cells, originating from B-cells and 
production of immunoglobulins (paraprotein) that can 
be detected in serum or urine by electrophoresis and/or 
immunofixation. The paraproteins secreted in MM are 
IgG (52%), IgA (21%) and only light chains (16%) 
and about 2% of cases are non-secretary. A majority of 
patients (about 80%) have osteolytic bone lesions (OBL) 
at diagnosis. Other presenting features are anaemia (72%), 
hypercalcaemia (13%), renal impairment (19%) and 
recurrent infections. 20% of cases are asymptomatic.[3,4] 
BM biopsy, biochemistry and comprehensive evaluation 
of skeleton are vital in the diagnosis of MM and to 
differentiate it from other plasma cell disorders [Figure 1]. 
The minimum criteria for making a diagnosis of MM 
include BM plasma cells >10%, detection of monoclonal 
proteins in serum or urine and the presence of end-organ 
damage. This group of symptoms is abbreviated as CRAB: 
Hypercalcaemia, renal impairment, anaemia and bony 
lesions.
Myeloma Bone Disease (MBD)
Nearly 90% of MM patients suffer from MBD during 
the course of the disease. Increased osteoclastic activity 
and suppressed osteoblastic function are a key factor in 
the pathophysiology of MBD.[5,6] Classically, these are 
punched out lytic lesions [Figure 2] without surrounding 
sclerosis around due to the absence of anabolic activity. 
Osteolytic lesions are located in close vicinity of plasma 
cells promoting the notion of interaction between 
myeloma cells and BM stromal cells leading to release 
of certain chemokines resulting in upregulation of 
osteoclastic and downregulation of osteoblastic activity. 
These lesions arise from medulla and move outward 
causing endosteal scalloping of the cortex and sometimes 
invading the periosteum leading to the formation of 
extraosseous mass.[6] Other types of lesions are solitary 
plasmactyomas and in about 10–15% of cases, there 
is a generalised osteopenia or osteoporosis. The axial 
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skeleton comprising the vertebrae, ribs, skull, and 
pelvis, along with the proximal parts of long bones 
are most commonly involved [Figure 3].[2,7] Sclerotic 
lesions in MM can also be seen in POEMS syndrome 
(polyneuropathy, organomegaly, endocrinopathy, 
monoclonal gammopathy and skin changes) which 
accounts for <1% of MM patients.[8] Osteolytic lesions 
rarely heal and they are persistent even when the 
disease is in remission. However, with the use of novel 
treatments, there is some evidence that certain agents 
such as bortezomib and increase osteoblastic activity 
in MM patients.[9]
Imaging has a key role in the assessment of disease at the 
time of diagnosis and subsequently for the monitoring 
of response to therapy. Imaging tools also highlight the 
presence or absence of any extramedullary disease and 
detect complications resulting from bone disease, for 
example, fractures. Conventional radiography (SKS) and 
new imaging modalities are used for the above purposes. 
All imaging techniques used have some advantages 
and disadvantages and might be appropriate for certain 
subgroups of MM.
Plain Radiography (Skeletal Survey [SKS])
SKS still remains the primary investigation for initial 
workup of MM, particularly where other modern facilities 
of imaging are unavailable. SKS includes about 20 plain 
films, taken as frontal (AP) and lateral (LA) views of 
chest, skull, whole spine, pelvis, humeri and femora. It 
covers a large area of the skeleton and highlights common 
complications of MM including lytic lesions, osteoporosis 
and fractures [Figure 2].[2,8] It is readily available and 
cheap and has a low radiation exposure. Cortical bone 
lesions are better defined on plain radiograph compared 
to magnetic resonance imaging (MRI).[4] However, SKS 
has a high false negative rate (30–70%), resulting in an 
underestimation of the stage and the diagnosis. The lytic 
lesions appear on radiographs when 30–75% of cancellous 
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Figure 1: Diagnostic criteria for multiple myeloma and related 
disorders 5. PC: Plasma cells, PP: Paraprotein
Figure 2: Plain radiographs of (a) skull, (b) humerus and 
(c) femora showing multiple lytic lesions
Figure 3: Skeletal site involvement in myeloma bone disease. 
Percentages mentioned are not meant to add up to 100% as most 
patients have multi-site involvement
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SKS provides limited information about ribs, sternum 
and scapulae. Furthermore, it is time-consuming with 
regular posture changes which could be painful for some 
patients who may already have fractures. In addition, it 
is difficult on SKS to differentiate between osteopenia 
due to MM and that due to other common causes such 
as postmenopause or senile osteoporosis.[11] As lytic 
lesions rarely heal, SKS does not help in the assessment 
of response to therapy [Table 1].
Computed Tomography (CT)
CT is another modality used in MM for the evaluation 
of bony lytic lesions [Figure 4]. Whole body CT was 
introduced to evaluate the whole skeleton. In some 
institutions, CT is used as initial imaging for the assessment 
of the spine and pelvis. It is an ideal investigation for the 
detection of early bone destruction. Extramedullary 
lesions, soft tissue mass, diffuse osteopenia, fractures and 
rare osteosclerotic lesions can also be detected on CT with 
higher sensitivity compared to SKS. Furthermore, it has 
been reported that CT reveals more lesions in areas that are 
poorly visualised on plain radiography. CT is superior in 
the assessment of fracture risk in unstable areas compared 
to both plain radiography and MRI.[12,13] CT is faster and 
the patient does not need to change postures as in plain 
radiography and there is no need of contrast media, for 
skeletal imaging which could be dangerous in MM. 
Patients who may already have compromised renal function 
due to the primary disease. Moreover, multidetector row 
CT (MDCT), a novel CT technique, is quite sensitive in 
the detection of smaller lytic lesions (<5 mm) particularly 
in the spine area. In addition, with this technique, there 
is a clear distinction between bony structures and soft 
tissues leading to less false positive results.[13,14] Another 
advantage of CT is its accuracy in a demonstration of 
extraosseous lesions and is a tool of choice for performing 
guided biopsy from spine or pelvis [Table 2]. CT is also 
used for planning of radiotherapy. CT can also be used in 
the detection of spinal cord compression; however, MRI 
is the preferred imaging modality in such patients.
When compared to plain radiography, CT carries a 
high radiation exposure (1.3–3 times higher)[11] and like 
conventional X-rays, is non-specific in the assessment 
of osteopenia. There is a relatively high false negative 
rate, particularly in cases of diffuse marrow infiltration 
and in early stages of the disease when there is no bone 
destruction.[15]
Whole-body low-dose CT (WBLDCT)
Due to high radiation exposure associated with whole-body 
CT, WBLDCT was introduced to overcome this drawback. 
The effective radiation dose in WBLDCT is much lower 
Figure 4: Whole-body computed tomography of a patient with 
multiple myeloma showing multiple lytic lesions
Table 1: Advantages and limitations of skeletal survey
Advantages Limitations
Readily available Low sensitivity (47.4%)
Inexpensive 10–20% lesions are missed
Detection of lytic lesions, fractures and osteoporosis Early stage lesions are missed (>30% cortical bone loss should be 
present before lytic lesions appear)
Low radiation exposure Poor tolerability (20 exposures, changing posture and elderly patients)
Not useful in the evaluation of treatment response as lesions rarely heal
Limited evaluation of certain areas, such as scapulae, sternum and ribs
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compared to standard CT (3.3 millisieverts [mSv] vs. 
36.6 mSv) and less than double that of SKS (3.3 [mSv] 
vs. 1.7 mSv).[12,13] Gleeson et al. reported a high diagnostic 
accuracy of WBLDCT in the detection of lytic lesions 
compared to SKS. More than half of the cases were 
upstaged and WBLDCT revealed additional information, 
for example, lymphadenopathy, hepatosplenomegaly and 
lung lesions which were not seen on SKS. Moreover, 
WBLDCT was superior to whole-body magnetic 
resonance imaging (WBMRI) in detection of residual 
lytic lesions.[13]
In brief, standard or low dose, CT is an alternative to 
plain radiography in the assessment of spine lesions in 
patients with symptoms of pain, as it provides a more 
comprehensive evaluation in a short period of time. 
Furthermore, in patients who are symptomatic in spite of 
negative SKS, CT may reveal additional lesions.[11]
MRI
There are two types of marrow; the red marrow or active 
haematopoietic and the yellow fatty inactive marrow. 
The red marrow converts to yellow fatty marrow as age 
advances, and in adults, haematopoietic marrow is mostly 
localised to the axial skeleton. There are five patterns 
of BM infiltration seen on MRI. These are: (1) Normal 
marrow (low tumour burden), (2) focal lesions (FLs), 
(3) variegated (salt and pepper appearance), (4) diffuse 
disease and (5) focal and diffuse infiltration. Thus, MRI 
appearance in MM patients will be dependent on the 
status of the underlying BM (red or yellow) and pattern 
of involvement.[16,17] The appearance of BM infiltration 
correlates with disease stage; normal and variegated 
pattern is consistent with Stage I, whereas focal and diffuse 
infiltration was associated with Stage II or III.[18] Normal 
BM appearances are present in about 50–75% of untreated 
Stage-I (according to Durie-Salmon staging system) and 
in 20% of untreated Stage-III disease.[17]
MRI sequences
The most common MRI sequences used in MM are 
T1-weighted, the T2-weighted with fat suppression, the 
short time inversion recovery (STIR) and the gadolinium 
T1-weighted with fat suppression. The classic myeloma 
lesions appear as low signal intensity on T1-weighted 
images and hyperintense on T2-weighted and STIR 
images. They show enhancement with gadolinium 
[Figure 5].[19]
Uses in MM
MRI is ideal in the detection of BM infiltration with 
myeloma cells even before bone destruction is evident on 
plain radiographs.[11,20] This is an investigation of choice 
Table 2: Role of computed tomography in multiple myeloma
Advantages Limitations
Detection of smaller lesions High radiation exposure (1.3–3 times)
Comprehensive evaluation in a short time Non specific in cases of osteopenia
High sensitivity (70.4%) High false negative rate (in diffuse or in the early phase of disease)
Detection of extramedullary disease Cost
Exact location of lesions (helpful in biopsy) Availability
Assessment of fracture risk
Planning for radiotherapy
Figure 5: T1 low, T2 isointense and post gadolinium T1 
enhancing focal vertebral lesion represents myelomatous 
deposits in the lumbar (white arrow) and sacral vertebral body. 
The associated lobulated enhancing soft tissue (red arrow) in 
relation to the sacral vertebral body is extending in the sacral 
neural foramina and compromising sacral nerve roots
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in cases of suspected spinal cord compression. It provides 
a comprehensive assessment of the extent and exact site 
of compression. MRI can be helpful in the differentiation 
of malignant from benign lesions and the evaluation of 
fracture risk. MM patients with >10 lesions on MRI have 
6–10 times higher risk of fracture compared to those who 
had either no or <10 lesions.[21] MRI has a key role in the 
detection of certain complications, for example, avascular 
necrosis of head of femur and amyloid deposits in heart 
or other soft tissues.[22]
Role of MRI in solitary plasmacytoma/smouldering 
MM/monoclonal gammopathy of underdetermined 
significance (MGUS)
MRI is also recommended in all cases of solitary bone 
plasmacytoma (SBP) and may reveal additional lesions 
which were not detected on plain radiography. In one 
study, MRI of spine detected additional foci in four out of 
12 patients.[23] In cases of smouldering MM (smouldering 
myeloma [SM]), MRI detected marrow abnormalities in 
30–50% of patients. Furthermore, in one study it was 
demonstrated that median time to start treatment was 
16 months in patients with abnormal MRI compared 
to 43 months with normal MRI (P < 0.01).[17,24] Based 
on recent published data, the presence of two or more 
lesions (>5 mm) on MRI is an indication to start therapy 
in these patients.[25] There are some studies using MRI 
in MGUS patients. In one study, evaluating 24 patients, 
the thoracolumbar spine MRI was normal in all MGUS 
cases versus only six of 44 MM patients who had normal 
findings.[26] In another study, Berg et al. reported BM 
abnormalities in 19% (n = 37) of cases. These patients 
had progression to MM in a shorter time compared to 
the cases with normal MRI.[27] It has also been noted 
that MGUS patients with abnormal MRI have a higher 
paraprotein and plasma cell percentage in BM compared 
to cases with normal MRI.[28] In brief, MRI is very helpful 
in cases of SBP, SM; however, in MGUS it may be useful 
in subgroups of patients who have a high risk of disease 
progression [Figure 6].
WBMRI
MRI provides valuable information about most of the 
axial skeleton; however, some bony areas may not be 
assessed properly including the skull, ribs and clavicle 
due to respiratory movements. To resolve this issue and 
to have a comprehensive view, WBMRI was introduced. 
WB MRI detects significant BM involvement in up to 20% 
of cases which are negative on SKS. In cases, where both 
modalities were positive MR shows more extensive bone 
morrow infiltration.[29] In another, large study (n = 611), 
WBMRI was compared with SKS. WBMRI revealed 
lesions in 74% of imaged sites compared to 43% with 
SKS. Moreover, in patients with normal SKS about half 
showed FLs on MRI. The MRI was superior to SKS, 
particularly in spine, pelvis and sternum. However, it 
was inferior to SKS in the detection of FLs in ribs and 
long bones.[30]
When compared to WBLDCT, WBMRI was found to be 
superior in both focal and diffuse disease appearances 
and revealed more lesions than WBLDCT.[13] In one 
study, Baur-Melnyk et al. evaluated 41 MM patients 
with WBMRI and WBMDCT. WBMRI was better in the 
detection of the number of lesions as well as the severity 
of involvement. WBMDCT under staged 11 patients 
compared with MRI.[15]
Evaluation of response to therapy in MM
MRI is also helpful in the evaluation of response to 
therapy. A complete response (CR) on MRI includes 
complete disappearance of the marrow abnormalities and 
partial remission (PR) would be a change from diffuse 
to the focal or variegated pattern.[31] The signal intensity 
reduction on T2-weighted images and resolution of 
enhancement of lesions, if previously present, will suggest 
a response to therapy. Sometimes FLs may persist or 
become more intense which could be due to inflammation 
Figure 6: T1 low, T2 isointense and post gadolinium T1 
enhancing focal C2 vertebral bodies shows marrow deposits 
(white arrow)
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or treatment-induced necrosis.[32,33] However, there 
are certain limitations as it takes about 9–12 months 
for lesions to resolve. The patient may have received 
granulocyte colony-stimulating factor (GCSF) during 
autologous stem cell transplant (ASCT) resulting in some 
changes in BM which can be difficult to differentiate from 
the disease. In such cases, MRI should be done at least 
1 month after ASCT.[34,35]
Prognostic significance
MM patients with the absence of BM abnormalities 
on MRI have better survival than those with abnormal 
findings on MRI.[36] Furthermore, the presence of >7 FLs 
on MRI is associated with shorter survival and resolution 
of FLs on post-treatment MRI indicates an improved 
outcome.[30]
In summary, WBMRI is an ideal first-line imaging tool 
to assess focal and diffuse disease; however, WBLDCT 
or plain radiography may be used as an adjunct to MRI 
to detect bony destruction and make an assessment of 
fracture risk. There is certain limiting factor [Table 3] to 
the use of MRI, for example, long acquisition time, patient 
may be claustrophobic or have metal devices in situ and 
the cost. In addition, gadolinium-based contrast media 
may lead to nephrogenic systemic fibrosis or nephrogenic 
fibrosing dermopathy.[37]
Positron Emission Tomography (PET)-CT
PET is a nuclear imaging technique in which positrons 
are used as radiolabels. The most commonly used is 
18-fluorine-fluoro-deoxyglucose (FDG). It is injected into 
the patient who should be fasting 4–6 h pre-procedure. 
Blood glucose is measured before FDG is injected and 
the patient undergoes scanning about 60–90 min after 
the injection.[4] Active lesions show FDG uptake that is 
greater than the background level. FDG accumulation 
is measured quantitatively as standardised uptake value 
(SUV). However, if the lesions are smaller than 5 mm in 
diameter, then FDG uptake should be considered positive 
regardless of SUV and lesions are indeterminate if SUV is 
<2.5 and lesion size is between 5 and 10 mm.[11,38] The PET 
component provides information about the function of the 
tissues (such as blood flow, oxygen use and metabolism of 
glucose) and CT provides structural/anatomical images. 
The combination of these two modalities can characterise 
the abnormal lesions both morphologically (e.g., soft 
tissues or bony) as well as functionally (e.g., active 
or inactive). Moreover, with the use of PET/CT, the 
lesions with subtle activity or very small size can also be 
detected which could be missed on PET images alone. 
Moreover, the scanning time is shorter with PET/CT 
(30 min) than with PET alone (about 1 h).[4,39,40] The extent 
of BM infiltration and the presence of extramedullary 
disease are important factors in MM patients and have 
prognostic significance.[41] PET/CT and MRI are very 
sensitive imaging modalities to detect these abnormalities 
[Figure 7].
Role of PET/CT at diagnosis
PET/CT provides information both about anatomy of 
lesions and highlights if involved area is still active 
Table 3: Advantages and limitations of magnetic resonance imaging
Advantages Limitations
Excellent for axial skeleton assessment Metallic implants
Best modality for cord compression/nerve root compression Claustrophobia
Excellent for detection of diffuse disease as well as focal lesions Availability




Greater sensitivity (83.3%) than plain radiography
Can be used response assessment
Useful in SBP
Maybe helpful in SM/MGUS
SBP: Solitary bone plasmacytoma, MGUS: Monoclonal gammopathy of underdetermined significance, SM: Smouldering myeloma
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or inactive (depending on FDG uptake). Furthermore, 
PET/CT detects osseous and extramedullary disease. In 
addition, there is a possibility to differentiate between 
diseased tissues and necrotic tissues resulting from 
radiation therapy.[40]
Fonti et al. reported results of 33 MM patients who 
underwent PET/CT, whole body Tc-sestamibi (Tc-MIBI) 
and MRI of spine and pelvis. PET/CT revealed 196 FLs 
(75 were in pelvis and spine), Tc-MIBI detected 63 focal 
defects (1 in spine and 9 in pelvis) and MRI showed 
51 FLs (40 in spine and 11 in pelvis). PET/CT detected 
significantly more lesions compared to Tc-MIBI and MRI. 
Another finding was that PET/CT and MRI findings were 
comparable in the detection of FLs alone or combination 
with a diffuse pattern. However, MRI and Tc-MIBI did 
better in the detection of diffuse pattern.[39] In another 
comparative study, Shortt et al. compared WBMRI with 
PET/CT and found a positive predictive value (PPV) of 
100% when both were used in combination; however, 
WBMRI was superior in detection of active disease with 
higher sensitivity (68% vs. 59%) and specificity (83% 
vs. 75%).[42] Likewise, Zamagni et al. evaluated 46 MM 
patients with whole-body X-rays, MRI of spine-pelvis 
and whole-body PET/CT. In this study, PET/CT was 
found to be superior to plain X-rays in 46% of patients 
(19% of patients were false negative on X-rays). In 35% 
of cases, PET/CT was better than MRI in the detection 
of myelomatous deposits in the areas which were out 
of a field of view of MRI. Conversely, in 30% of cases, 
PET/CT did not reveal any lesions in the spine and pelvic 
areas where MRI revealed BM involvement, particularly 
in a diffuse pattern.[43] Bredella et al. evaluated 13 MM 
patient with FDG PET. In this study, 4 out of 13 patients 
were upstaged by FDG PET resulting in a change in future 
management.[44] The sensitivity and specificity of FDG 
PET to detect the medullary involvement of MM was 
85% and 92%, respectively.
Recently, Bartel et al. demonstrated in a large group 
of patients that the number and FDG positivity of 
FLs on PET/CT were correlated with high beta-two 
microglobulin, C-reactive protein (CRP) and lactate 
dehydrogenase levels. Furthermore, the presence of 
>3 FDG-avid FLs was associated with inferior overall 
and event-free survival.[45] In another prospective study 
(n = 43) PET/CT was positive in 38 out of 41 (sensitivity 
92.7%) known lytic lesions due to MM; furthermore, 71 
additional lesions were depicted by PET/CT which were 
not seen on plain radiography in 14 patients which resulted 
in a change in management plan in about 14% of patients. 
The PPV for the active disease was 100% for the focal or 
focal/diffuse pattern and 75% for diffuse BM uptake.[46]
PET/CT is also a useful modality in the detection of 
extramedullary disease and one study additional lesions 
were noted in up to 30% of patients who were diagnosed 
as SBP by MRI. PET/CT is an ideal modality to monitor 
Figure 7: F18 18-fluorine-fluorodeoxyglucose positron emission tomography-computed tomography scan images of a 43-year-old 
patient with multiple myeloma (a) Baseline scan shows expansile lytic lesion in right sacral ala (max SUV 7.2) (b) Post cycle 4 
LCD redemonstrated sacral lesion with interval reduction in uptake (max SUV 2.4 = Liver)
b
a
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nonsecretory MM patients and to detect osteonecrosis of 
jaw related to bisphosphonate therapy.[41,47,48]
Role of PET/CT in the assessment of response to 
therapy
PET/CT is not only capable of detecting bone lesions 
and extramedullary disease but also has the ability to 
distinguish active disease from post-therapy necrotic 
tissue. It is well known that bone defects due to MM 
rarely heal; thus, conventional radiography and CT may 
not be of much help in assessing the disease response 
post-therapy. The abnormalities noticed on MRI do change 
or disappear in responding patients; however, it takes 
about 9–12 months for these changes to be appreciated on 
MRI.[35,49] In contrast, the changes in PET appear within a 
few hours to 3–4 weeks of effective treatment, making it 
the investigation of choice for restaging. The persistence 
of FDG avid lesions on PET/CT post-transplant is a poor 
prognostic factor and correlates with early relapse (within 
6 months period).[35] In one study, 10 patients had post-
treatment PET/CT scans and nine of them were negative 
and one was positive for the active disease. None of 
PET/CT negative patients showed any abnormality on 
MRI and CT. These patients were followed up clinically 
for at least 6 months and eight of them remained in 
remission.[44] Zamagni et al. evaluated 23 patients 
3 months post autologous transplantation with PET/CT 
and MRI. 15 patients (65%) showed normalisation of 
PET/CT scans and in 12 of these patients, there was 
≥90% reduction in the level of M-protein. On the other 
hand, of these 15 patients, MRI pattern was normal in 
eight while in 7 patients MRI was either unchanged or 
revealed a low number of lesions.[43] The presence of 
residual FDG activity after induction therapy predicts 
poor outcome. Bartel et al. reported that complete FDG 
suppression before transplantation correlates with superior 
overall survival (OS) and event-free survival (EFS). At 
30 months, there was a significant difference in OS (92% 
vs. 71%) and EFS (89% vs. 63%) between the patients 
with negative scans and those who did not achieve 100 % 
suppression, respectively.[45]
In brief, PET/CT is an ideal imaging modality to scan 
whole-body in one procedure and in a reasonable time 
frame. It provides both functional and morphological 
characteristics of the lesion. It is most sensitive modality 
in the evaluation of treatment response, particularly in 
non-secretary MM. PET/CT is very useful in the detection 
of extramedullary disease and complications of MM 
(e.g., infections and ONJ). There are certain pitfalls of 
PET/CT which should be kept in mind while making an 
assessment. For example, there is high radiation exposure 
and smaller lesions may be missed due to limited PET 
resolution. There is a risk of false negative results in 
cases of diffuse disease involving the spine and pelvis. 
Inflammation, infections and GCSF treatment may 
increase FDG activity while radiotherapy may decrease 
FDG uptake on PET/CT [Table 4].
99-m MIB
99-m Tc-labelled 2-methoxyisobutylisonitrile (MIBI) 
is a radiopharmaceutical which emits X-rays and has 
a predilection to accumulate in tissues with high cell 
density and mitochondrial activation which could be 
found in malignant lesions. MIBI actively concentrated 
in myeloma tissues and bone lesions and is more sensitive 
Table 4: Advantages and limitations of positron emission tomography‑computed tomography
Advantages Limitations
Ability to detect both focal and diffuse disease High radiation exposure
Differentiation of active and non‑active lesions Subcentimeter lesions may be missed on PET
Ideal for response evaluation in non‑secretory myeloma Inflammation, infection, GCSF and radiotherapy can affect FDG uptake
Detection of osteonecrosis of jaw Availability
Prognostic significance (e.g., three or more lesions 
confers poor prognostic factor and the presence of FDG 
avidity post induction correlates with poor outcome)
Detection of extramedullary disease
FDG: 2‑fluoro‑2‑deoxy‑D‑glucose, GCSF: Granulocyte colony‑stimulating factor, PET: Positron emission tomography
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to plain radiography.[11,50] It has been demonstrated that 
MIBI localises inside the plasma cells.[51] There are 
different patterns of MIBI uptake in MM; physiological, 
focal, diffuse and extramedullary uptake. Focal uptake 
indicates active myeloma, but diffuse uptake without 
focal positivity does not support active myeloma.[52,53] 
Mele et al. evaluated 397 cases of MM with MIBI and 
conventional X-rays. In a series of 229 MIBI scans done 
at diagnosis, 146 (64%) were positive and 81 cases were 
discordant with X-ray results. The sensitivity was higher 
(77%) with MIBI compared to X-rays (45%). In addition, 
MIBI results were positively correlated with CRP, BM 
infiltration and bone pain. In 168 follow-up scans, 
MIBI presented high specificity in patients with CR and 
correlated with response to therapy.[50] In another study, 
MIBI was found very effective in determining the active 
myeloma disease both at diagnosis and relapse.[54] It has 
been reported that MIBI has the ability to detect active 
lesions in non-secretory MM and MIBI results directly 
correlate with clinical outcome after ASCT.[53,55]
However, MIBI is inferior to PET/CT and MRI in the 
detection of myelomatous involvement. In one study, 
FDG-PET was better than MIBI in the detection of skeletal 
lesions (93.3% vs. 80%), soft tissue lesions (68.4% vs. 
89.5%) and BM infiltration (100% vs. 80%).[56] Fonti et al. 
reported a comparison of PET/CT, MIBI and MRI. In this 
study, PET/CT was superior to MIBI in the detection of 
FLs but inferior in cases of the diffuse disease. Likewise, 
MIBI was inferior to MRI in the detection of disease, 
particularly in spine and pelvis.[39] In brief, MIBI is a 
useful whole-body imaging modality in MM particularly 
if PET/CT and MRI are not available.
Bone Scan (Bone Scintigraphy)
Bone scan is a whole-body imaging to detect metabolic 
activity in the entire skeleton using 99m Tc-diphosphonate 
as a radiopharmaceutical. The mechanism of uptake 
is directly correlated with blood flow and osteoblastic 
activity of the lesion. In MM, the bony lesions are due to 
increased osteoclastic activity and suppressed or absent 
osteoblastic function; thus, a bone scan is not very useful 
in these patients. Ludwig et al. reported a comparison of 
bone scan and plain radiography in 41 MM patients. In 
this study, plain radiography was superior to a bone scan. 
Plain radiography detected 97 myeloma-related lesions 
compared to only 16 with bone scintigraphy, giving a 
sensitivity of 91% and 46%, respectively.[57] In another 
study, 27 MM patients were monitored for about 5 years 
with bone scintigraphy and SKS every 6 months. The SKS 
revealed myeloma-related lesions with high sensitivity 
and specificity at the diagnosis, in follow-up cases and 
the assessment of bone pain than bone scintigraphy.[58] 
To sum up, a bone scan is not routinely used in MM, the 
major reason being the primary dysfunction of osteoblasts 
in MM and 99-m Tc-diphosphonate uptake is dependent on 
osteoblastic activity. However, a bone scan can be helpful 
in the detection of fracture sites.
Dual-energy X-ray Absorptiometry (DXA)
DXA scan is a method of choice for the diagnosis of 
osteoporosis. There is an increased risk of early vertebral 
fracture in MM patients who have reduced lumbar spine 
bone mineral density (BMD). This makes DXA scan an 
important test to consider in these patients particularly 
when there is no focal lytic lesion.[47,59] However, DXA 
may not be able to differentiate between myeloma-
related osteoporosis from other causes of osteoporosis. 
Abildgaard et al. evaluated 34 newly diagnosed MM 
patients with DEXA and demonstrated that osteopenia of 
spine correlates with increased risk of vertebral fracture. 
DEXA may be useful to identify high-risk patients who 
may need intensive chemotherapy or bisphosphonate 
treatment.[60] In one study, 66 MM patients were monitored 
with DEXA scan to assess BMD. Patients were treated 
either with conventional therapy or intensive therapy with 
peripheral blood stem cell transplantation. After intensive 
therapy, the increase of lumbar spine BMD was higher in 
men than women. There was a correlation with changes 
in BMD and M-protein in urine or serum.[61] The presence 
of lytic lesions, vertebral collapse and spinal osteophytes 
may cause difficulties in some patients to do DEXA scan. 
In selected cases femoral and radial BMD can be relied on.
Conclusion
Due to the complex nature of the human skeleton, a 
single imaging technique cannot provide a comprehensive 
picture of the whole body. All imaging modalities have 
some advantages and disadvantages. Plain radiography is 
still accepted as a primary investigation for the screening 
of MM patients. However, WBMRI, CT and PET/CT 
scans have replaced plain radiography in some institutions 
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and should be considered depending on availability. The 
cost of these imaging tools and the availability of trained 
professionals are major obstacles to using them widely. 
WBMRI should be performed in the cases of MM with 
normal SKS at diagnosis, particularly in patients with 
SBP. An urgent MRI is indicated in suspected spinal 
cord compression. CT of the spine may be an alternative 
if MRI is not available. CT may also be considered for 
further evaluation of lesions which are inconclusive 
on MRI to detect structural damage of the bone and 
extramedullary masses. PET/CT is most sensitive in 
diagnosing extramedullary disease and is also considered 
ideal in patients with non-secretory MM. In addition, 
PET/CT appears to be better in the assessment of response 
to therapy than other available techniques and should 
be considered. Based on available data, the MIBI, bone 
and DEXA scans do not have a significant role in the 
management of MM and are not used routinely.
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